Induction of potent antitumor immunity by intradermal DNA injection using a novel needle-free pyro-drive jet injector.
DNA vaccine
antitumor immunity
generation of CTLs
intradermal injection
pyro-drive jet injector
Journal
Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776
Informations de publication
Date de publication:
Jan 2023
Jan 2023
Historique:
revised:
28
07
2022
received:
21
03
2022
accepted:
31
07
2022
pubmed:
25
8
2022
medline:
5
1
2023
entrez:
24
8
2022
Statut:
ppublish
Résumé
The current success of mRNA vaccines against COVID-19 has highlighted the effectiveness of mRNA and DNA vaccinations. Recently, we demonstrated that a novel needle-free pyro-drive jet injector (PJI) effectively delivers plasmid DNA into the skin, resulting in protein expression higher than that achieved with a needle syringe. Here, we used ovalbumin (OVA) as a model antigen to investigate the potential of the PJI for vaccination against cancers. Intradermal injection of OVA-expression plasmid DNA into mice using the PJI, but not a needle syringe, rapidly and greatly augmented OVA-specific CD8
Identifiants
pubmed: 36000926
doi: 10.1111/cas.15542
pmc: PMC9807518
doi:
Substances chimiques
COVID-19 Vaccines
0
Ovalbumin
9006-59-1
Vaccines, DNA
0
DNA
9007-49-2
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
34-47Subventions
Organisme : Daicel Corporation
Organisme : Ministry of Education, Culture, Sports, Science and Technology, Japan
Informations de copyright
© 2022 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.
Références
Vaccine. 2013 Jul 25;31(34):3392-5
pubmed: 23176978
Int Arch Allergy Appl Immunol. 1980;61(3):253-8
pubmed: 6243610
Curr Opin Immunol. 2011 Jun;23(3):421-9
pubmed: 21530212
Gene Ther. 2006 Dec;13(23):1619-27
pubmed: 16871232
J Leukoc Biol. 2000 Dec;68(6):793-806
pubmed: 11129646
Gene. 1991 Dec 15;108(2):193-9
pubmed: 1660837
J Pharm Sci. 2019 Jul;108(7):2415-2420
pubmed: 30849461
Front Immunol. 2018 Jul 16;9:1643
pubmed: 30061897
Nat Methods. 2012 Jul;9(7):671-5
pubmed: 22930834
Bio Protoc. 2014 Jul 5;4(13):
pubmed: 29170744
JAMA Netw Open. 2021 Feb 1;4(2):e2035693
pubmed: 33560425
Oncoimmunology. 2012 Dec 1;1(9):1537-1545
pubmed: 23264900
Methods Mol Biol. 2015;1325:289-302
pubmed: 26450396
Int J Pharm. 2021 Nov 20;609:121200
pubmed: 34662643
Biotechnol Bioeng. 2008 Mar 1;99(4):846-54
pubmed: 17879304
AAPS PharmSciTech. 2019 Dec 9;21(1):19
pubmed: 31820256
Vaccine. 2003 Sep 8;21(25-26):4036-42
pubmed: 12922140
Adv Sci (Weinh). 2021 Aug;8(15):e2004595
pubmed: 34096197
AAPS J. 2009 Dec;11(4):671-81
pubmed: 19834816
Immunity. 1997 Jun;6(6):715-26
pubmed: 9208844
Biotechnol Bioeng. 2000 Jun 20;68(6):697-704
pubmed: 10799996
Inflammation. 2003 Aug;27(4):247-55
pubmed: 14527177
Future Virol. 2021 Nov;:
pubmed: 34858516
Front Med (Lausanne). 2022 Jan 18;8:806641
pubmed: 35118097
J Pharm Sci. 2021 Mar;110(3):1310-1315
pubmed: 33253725
Risk Manag Healthc Policy. 2021 May 20;14:2079-2087
pubmed: 34045909
Immunol Lett. 2010 Jan 18;128(1):29-35
pubmed: 19895847
Front Immunol. 2013 May 16;4:114
pubmed: 23720661
Mol Ther. 2017 Dec 6;25(12):2635-2647
pubmed: 28958578
J Cosmet Dermatol. 2021 Dec;20(12):3793-3801
pubmed: 33682249
Biol Pharm Bull. 2006 Jul;29(7):1511-5
pubmed: 16819202
Gene. 2021 Jul 1;788:145664
pubmed: 33887371
J Leukoc Biol. 2001 Dec;70(6):849-60
pubmed: 11739546
Semin Cell Dev Biol. 2021 Jul;115:3-9
pubmed: 33423930
Expert Rev Vaccines. 2019 May;18(5):505-521
pubmed: 31009255
Proc Natl Acad Sci U S A. 2013 Feb 5;110(6):2082-7
pubmed: 23341631
Micromachines (Basel). 2021 Apr 14;12(4):
pubmed: 33919925
Curr Top Microbiol Immunol. 2012;351:159-79
pubmed: 21416266
Cancer Res. 2004 Feb 1;64(3):1152-6
pubmed: 14871851
Front Pharmacol. 2016 May 26;7:137
pubmed: 27303298
Cancer Sci. 2023 Jan;114(1):34-47
pubmed: 36000926
Microb Biotechnol. 2021 Jul;14(4):1580-1593
pubmed: 33993638
Phys Rev E Stat Nonlin Soft Matter Phys. 2010 Nov;82(5 Pt 1):051602
pubmed: 21230483